Cargando…

N‐terminal pro‐brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia

Patient‐related factors are of prognostic importance in acute myeloid leukemia (AML). Likewise, cardiac disorders may limit the tolerance of intensive therapy. Little is known about the prognostic value of N‐terminal pro‐brain natriuretic peptide (NT‐proBNP). We analyzed NT‐proBNP levels at diagnosi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Graf, Irene, Greiner, Georg, Marculescu, Rodrig, Gleixner, Karoline V., Herndlhofer, Susanne, Stefanzl, Gabriele, Knoebl, Paul, Jäger, Ulrich, Hauswirth, Alexander, Schwarzinger, Ilse, Thalhammer, Renate, Kundi, Michael, Hoermann, Gregor, Mitterbauer‐Hohendanner, Gerlinde, Valent, Peter, Sperr, Wolfgang R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107495/ https://www.ncbi.nlm.nih.gov/pubmed/36588398 http://dx.doi.org/10.1002/ajh.26805

Ejemplares similares

Incidence of symptomatic Covid‐19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population
por: Graf, Irene, et al.
Publicado: (2022)

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1(T315I)+ clones in TKI-resistant CML
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2019)

Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis
por: Berger, Daniela, et al.
Publicado: (2021)

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis
por: Schneeweiss, Mathias, et al.
Publicado: (2018)

Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56(bright) NK cell subpopulations in patients with acute myeloid leukemia and supports their activation
por: Cuapio, Angélica, et al.
Publicado: (2016)

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML
por: Valent, Peter, et al.
Publicado: (2017)

FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H()
por: Valent, Peter, et al.
Publicado: (2013)

Identification of CD203c as a New Basophil-Specific Flow-Marker in Ph(+) Chronic Myeloid Leukemia
por: Sadovnik, Irina, et al.
Publicado: (2022)

CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V(+) Neoplastic Mast Cells
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2022)

Phenotyping and Target Expression Profiling of CD34(+)/CD38(−) and CD34(+)/CD38(+) Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
por: Blatt, Katharina, et al.
Publicado: (2018)

The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells
por: Stefanzl, Gabriele, et al.
Publicado: (2017)

Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia
por: Cerny-Reiterer, Sabine, et al.
Publicado: (2014)

Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia
por: Cerny-Reiterer, Sabine, et al.
Publicado: (2014)

Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm
por: Füreder, Wolfgang, et al.
Publicado: (2016)

Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma
por: Blatt, Katharina, et al.
Publicado: (2016)

Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches
por: Valent, Peter, et al.
Publicado: (2019)

Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia
por: Eisenwort, Gregor, et al.
Publicado: (2021)

Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond
por: Sprinzl, Bettina, et al.
Publicado: (2021)

Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms
por: Hoermann, Gregor, et al.
Publicado: (2015)

Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML
por: Valent, Peter, et al.
Publicado: (2019)

Adequate scattergram interpretation increases the reliability of automated polymorphonuclear (pmn) cell counts from ascitic fluid of patients with liver cirrhosis
por: Haslacher, Helmuth, et al.
Publicado: (2021)

Myelomonocytic skewing in chronic myelomonocytic leukemia: phenotypic, molecular and biologic features and impact on survival
por: Geissler, Klaus, et al.
Publicado: (2021)

Clonal Hematopoiesis of Indeterminate Potential: A Multidisciplinary Challenge in Personalized Hematology
por: Hoermann, Gregor, et al.
Publicado: (2020)

BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph(+) chronic myeloid leukemia
por: Peter, Barbara, et al.
Publicado: (2022)

Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives
por: Valent, Peter, et al.
Publicado: (2018)

Identification of a Leukemia-Initiating Stem Cell in Human Mast Cell Leukemia
por: Eisenwort, Gregor, et al.
Publicado: (2019)

Preclinical human models and emerging therapeutics for advanced systemic mastocytosis
por: Arock, Michel, et al.
Publicado: (2018)

BTK inhibition is a potent approach to block IgE‐mediated histamine release in human basophils
por: Smiljkovic, D., et al.
Publicado: (2017)

Engraftment in NSG(SCF) mice correlates with the WHO category and prognosis in systemic mastocytosis
por: Willmann, Michael, et al.
Publicado: (2023)

Overexpression of PDE4A Acts as Checkpoint Inhibitor Against cAMP-Mediated Immunosuppression in vitro
por: Schmetterer, Klaus G., et al.
Publicado: (2019)

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML)
por: Herrmann, Harald, et al.
Publicado: (2012)

Biological properties of bone marrow plasma cells influence their recovery in aspirate specimens: impact on classification of plasma cell disorders and potential bias to evaluation of treatment response
por: Demyanets, Svitlana, et al.
Publicado: (2020)

Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis
por: Greiner, Georg, et al.
Publicado: (2020)

A Multidisciplinary Intervention in Childhood Obesity Acutely Improves Insulin Resistance and Inflammatory Markers Independent From Body Composition
por: Mayerhofer, Ernst, et al.
Publicado: (2020)

Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia
por: Gleixner, Karoline V., et al.
Publicado: (2017)

The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML): A representative and useful real-life data source for further biomedical research
por: Geissler, Klaus, et al.
Publicado: (2019)

In vitro effects of histamine receptor 1 antagonists on proliferation and histamine release in canine neoplastic mast cells
por: Gamperl, Susanne, et al.
Publicado: (2020)

Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site
por: Hadzijusufovic, Emir, et al.
Publicado: (2017)

Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts
por: Valent, Peter, et al.
Publicado: (2023)

Critically ill patients with cancer: chances and limitations of intensive care medicine—a narrative review
por: Schellongowski, Peter, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_o0mqsjflmoqvla4kcfiia0l33v